医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Taiyo Pacific Partners Becomes Major Shareholder in Sosei Group Corporation with Stake over 5%

2018年06月04日 AM10:29
このエントリーをはてなブックマークに追加


 

TOKYO

Taiyo Pacific Partners announced today that it has accumulated in excess of 5% in Sosei Group Corporation (4565) to become Sosei’s second largest shareholder. The company (or “Sosei”) is an international biotechnology company focused on discovering, developing and delivering new medicines that could contribute to improving the health and quality of life of people around the world. Taiyo Pacific Partners is a pioneer of friendly engagement investing in Japan and has been proactively working with senior management at its portfolio companies to enhance shareholder value for over 14 years.

Brian K. Heywood, Chief Executive Officer and Managing Partner of Taiyo Pacific Partners, said, “I am excited about the strategic investments the Company has made to augment their technology and business. With the addition of Heptares Therapeutics, Sosei has a differentiated drug discovery platform and a burgeoning pipeline of partnered and in-house drugs with the potential to address multiple diseases afflicting billions around the world. As with all of our portfolio companies, we look forward to working with management and supporting their continued growth.”

Michael A. King, Chief Investment Officer and Managing Partner of Taiyo Pacific Partners, said, “While the quarter-by-quarter earnings and cash flow will be lumpy during this investment phase, we are excited about the long-term potential for Sosei’s drug discovery process to bring multiple novel candidates into trials over the next 18-24 months. Sosei’s balanced model of partnership, strategic tie-ups, and in-house R&D is geared toward optimizing upside while diversifying development and commercial risk across a range of clients and disease indications. We believe that patient investors will be well rewarded for their investment in Sosei.”

Taiyo Pacific Partners, located in Kirkland, Washington, was founded in 2003 by Asia-focused professionals dedicated to friendly shareholder activism in Japan and other Asian countries. The firm currently manages approx. $2.5 billion in Japan focused funds. All strategies employ a friendly activist approach. Investors include international blue-chip investors such as major pension plans, Sovereign Wealth Funds, and endowments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180603005163/en/

CONTACT

Taiyo Pacific Partners
Brian K. Heywood, 425-896-5300
taiyo_media@tppllc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究